Astellas Pharma Inc. revealed Tuesday that it has spent the last year attempting to acquire CV Therapeutics Inc., but the biotech rejected its latest $1 billion offer and declined to engage in further discussions. (BioWorld Today)

SAN FRANCISCO - At the 27th annual J.P. Morgan Healthcare Conference, discussions from the crowded hallways to the private meetings rooms predicted that biotech is in for a year of consolidation, but that the industry will emerge leaner and stronger. (BioWorld Today)